|
NR. 1/2008
|
|
|
|
|
|
|
|
|
Nowe trendy w
leczeniu jaskry – preparaty łączone, neuroprotekcja
New Trends in Glaucoma Treatment – Fixed-Combination Therapy,
Neuroprotection
Monika Udziela, Mira Gacek, Danuta
Chudzyńska-Zawadzka, Jerzy Szaflik
Katedra i Klinika Okulistyki II Wydziału Lekarskiego
Warszawskiego Uniwersytetu Medycznego
Samodzielny Publiczny Kliniczny Szpital Okulistyczny w Warszawie
Kierownik: prof. dr hab. n. med. Jerzy Szaflik |
|
|
|
|
|
|
|
| Summary: |
In accordance to EGS
Guidelines for Glaucoma the goal of glaucoma treatment
can be summarized as follows: visual function
preservation adequate to individual needs with minimal
side effects, for the expected lifetime of the patient,
without any disruption of his/her normal activities, at
a sustainable cost.
Combined medicines preparations are preferable to two
separate instillations of the same agents due to
improved compliance and positive influence on dosing
schedule and quality of life. Glaucoma patients are
frequently old and may have diminished cognitive
abilities and other ailments which may reduce their
accuracy to administer medicine. Drug interactions and
tolerance must be taken into consideration. Ocular
irritation may be decreased by reducing number of
preserved eye drops.
Nowadays glaucoma is defined as neurodegenerative
disease. Therefore a need for therapy exists, which slow
glaucomatous damage progression by blocking the
mechanism leading to apoptosis. Such type of therapy is
called neuroptrotection. Although there is good
laboratory evidence for glaucoma neuroprotection by
several agents, the evidence from randomized clinical
trials in human beings is lacking. |
| |
|
| Key words: |
glaucoma, intraocular
pressure, combined medications, quality of life,
neuroprotection, apoptosis. |
|
|
|
|
|
|
|
|
